

DAFTAR PUSTAKA

1. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Vol. 84, International Immunopharmacology. Elsevier B.V.; 2020.
2. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Vol. 1856, Biochimica et Biophysica Acta - Reviews on Cancer. Elsevier B.V.; 2015. p. 73–85.
3. Tao ZQ, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2015 Jun 15;72(2):333–8.
4. Solikhah S, Promthet S, Hurst C. Awareness level about breast cancer risk factors, barriers, attitude and breast cancer screening among Indonesian women. Asian Pacific Journal of Cancer Prevention. 2019;20(3):877–84.
5. Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. In: Progress in Molecular Biology and Translational Science. Elsevier B.V.; 2017. p. 1–32.
6. Coccia PF, Pappo AS, Beaupin L, Borges VF, Borinstein SC, Chugh R, et al. Adolescent and young adult oncology, version 2.2018: Clinical practice guidelines in oncology. Vol. 16, JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press; 2018. p. 66–97.
7. Johnson RH, Anders CK, Litton JK, Ruddy KJ, Bleyer A. Breast cancer in adolescents and young adults. Vol. 65, Pediatric Blood and Cancer. John Wiley and Sons Inc.; 2018.



8. Li Z, Lianos GD, Ignatiadou E, Harissis H v., Mitsis M. Breast cancer in men: an overview. Vol. 69, Updates in Surgery. Springer-Verlag Italia s.r.l.; 2018. p. 3–7.

9. Bagian DI, Onkologi B, Sakit R, Pusat U, Denpasar S, Made N, et al. KANKER PAYUDARA PADA WANITA USIA MUDA.
10. Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. Vol. 472, Virchows Archiv. Springer Verlag; 2018. p. 697–703.
11. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015 Nov 1;24:S26–35.
12. Li J, Chen Z, Su K, Zeng J. Original Article Clinicopathological classification and traditional prognostic indicators of breast cancer [Internet]. Vol. 8, Int J Clin Exp Pathol. 2015. Available from: www.ijcep.com/
13. Wang M, Klevebring D, Lindberg J, Czene K, Grönberg H, Rantalainen M. Determining breast cancer histological grade from RNA-sequencing data. Breast Cancer Research. 2016 May 10;18(1).
14. Subiyanto D, Kadi TA, Ismayah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Subtipe Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan Grading Histopatologi. Media Penelitian dan Pengembangan Kesehatan. 2021 Dec 13;31(3):193–202.
15. Warjianto W, Soewoto W, Alifianto U, Wujoso H. Hubungan Reseptor Estrogen, Reseptor Progesteron dan Ekspresi Her-2/Neu Dengan Grading Histopatologi pada Pasien Kanker Payudara di RSUD dr. Moewardi Surakarta. Smart Medical Journal. 2020;3(2):96.
16. Kim HJ, Kim S, Freedman RA, Partridge AH. The impact of young age at diagnosis (15–49 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast. 2022 Feb 1;61:77–83.



17. Box BA, Russel CA. Breast Cancer: in Manual of Clinical Oncology. 6th ed. Los Angeles: Lipincott Williams & Wilkins; 2009.
18. Guyton A, Hall J. Text book of medical Physiology. In 2021.
19. Pandya S, Moore RG. Breast Development and Anatomy [Internet]. Available from: www.clinicalobgyn.com
20. Aihw. Breast cancer in young women: key facts about breast cancer in women in their 20s and 30s (full publication; 14Oct2015 edition) (AIHW).
21. Lester SC. The Breast in Text book of Robbin's Pathologic Basic of Disease; Chapter 23. 6th ed. Phil. W.B Saunders Co; 2010.
22. Willet WC, Rockhill B, Hankinson SE, Hunter DJ, Colditz GA. Epidemiology and Non Genetic Causes of Breast Cancer. 2nd ed. Philadelphia: Lippincott Williams and Wilkins;
23. Age standardized (World) incidence rates, breast, all ages. Available from: <https://gco.iarc.fr/today>
24. Indonesia.
25. Indra I, Sampepajung D, Haryasena H, Faruk M. CORRELATION BETWEEN VASCULAR ENDOTHELIAL GROWTH FACTOR-A (VEGF-A) SERUM WITH CLINICAL STAGE, HISTOPATHOLOGIC GRADING AND ESTROGEN RECEPTOR STATUS BREAST CANCER PATIENT IN MAKASSAR. International Journal of Surgery and Medicine. 2020;(0):1.
26. Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Women (BCY4). Annals of Oncology. 2020 Jun 1;31(6):674–96.



ata Laksana Kanker Payudara.

28. Kementerian Kesehatan Republik Indonesia [Internet]. [cited 2023 Apr 5]. Available from: <https://www.kemkes.go.id/article/view/22020400002/health-care-equality-for-breast-cancer-patients.html>
29. Azim HA, Partridge AH. Biology of breast cancer in young women [Internet]. 2014. Available from: <http://breast-cancer-research.com/content/16/4/427>
30. Anders CK, Tichy JR, Lim E. Breast Cancer in Adolescents and Young Adults: A Review With a Focus on Biology. Vol. 11, Journal of the National Comprehensive Cancer Network |. 2013.
31. Hussein A. Assi, Katia E. Khoury, Haifa Dbouk, Lana E. Khalil, Tarek H. Mouhieddine, Nagi S. El Saghir. Epidemiology and Prognosis of Breast Cancer in Young Women. J Thorac Dis. 2013;
32. Desreux JAC. Breast cancer screening in young women. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2018 Nov 1;230:208–11.
33. Gazalla Ayub S, Rasool S, Ayub T, Khan SN, Wani KA, Andrabi KI. Mutational analysis of the BRCA2 gene in breast carcinoma patients of Kashmiri descent. Mol Med Rep. 2014 Feb 1;9(2):749–53.
34. Aziyah A, Sumarni S, Ngadiyono N. FAKTOR RESIKO YANG BERHUBUNGAN DENGAN KEJADIAN KANKER SERVIK; STUDI KASUS DI RSUP DR. KARIADI SEMARANG. Jurnal Riset Kesehatan. 2017 Dec 8;6(1):20–5.
35. Mehrgou A, Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran. 2016;30(15):369.
36. Dewi GAT, Lucia Yovita Hendrati NIDN 0019106802. Analisis Risiko Kanker Berdasarkan Riwayat Pemakaian Kontrasepsi Hormonal dan Usia Menarche.



37. PERABOI. Panduan Penatalaksanaan Kanker Perhimpunan Ahli Bedah Onkologi Indonesia. 2nd ed. Panduan Penatalaksanaan Kanker 2020. Jakarta; 2020. 1–44 p.
38. Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). *Annals of Oncology*. 2020 Jun 1;31(6):674–96.
39. He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T, et al. A review on methods for diagnosis of breast cancer cells and tissues. *Cell Prolif*. 2020 Jul 1;53(7):e12822.
40. Australian Institute of Health and Welfare. Breast cancer in young women: key facts about breast cancer in women in their 20s and 30s. Canberra; 2015.
41. Agustina R. Peran Derajat Differensiasi Histopatologik dan Stadium Klinis Pada Rekurensi Kanker Payudara. Vol. 4. 2015.
42. Khambri D, Harahap WA, Yanwirasti Y, Haryono SJ, Jamsari J. Pentingnya Pemeriksaan Androgen Reseptor (AR) Terhadap Penderita Karsinoma Payudara di Sumatera Barat. *Biotrends*. 2016 Jun 6;6(2):39–45.
43. Mehrgou A, Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. *Med J Islam Repub Iran [Internet]*. 2016 [cited 2023 Feb 10];30(15):369. Available from: <http://mjiri.iums.ac.ir>
44. Jin YH, Hua QF, Zheng JJ, Ma XH, Chen TX, Zhang S, et al. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer. *Cellular Physiology and Biochemistry*. 2018 Sep 1;49(1):271–81.
45. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the international expert consensus on the primary therapy of early breast Cancer *Annals of Oncology*. 2013 Sep 1;24(9):2206–23.



46. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: The role of histological grade. *Breast Cancer Research*. 2010;12(4).
47. Jin YH, Hua QF, Zheng JJ, Ma XH, Chen TX, Zhang S, et al. Diagnostic Value of ER, PR, FR and HER-2-Targeted Molecular Probes for Magnetic Resonance Imaging in Patients with Breast Cancer. *Cellular Physiology and Biochemistry*. 2018 Sep 1;49(1):271–81.
48. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst*. 2009 May;101(10):736–50.
49. Khambri D, Harahap WA, Yanwirasti Y, Haryono SJ, Jamsari J. Pentingnya Pemeriksaan Androgen Reseptor (AR) Terhadap Penderita Karsinoma Payudara di Sumatera Barat. *Biotrends [Internet]*. 2016 Jun 6 [cited 2023 Feb 11];6(2):39–45. Available from: <https://terbitan.biotek.lipi.go.id/index.php/biotrends/article/view/130>
50. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Vol. 22, *Breast Cancer Research*. BioMed Central Ltd; 2020.
51. Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. *Cancer Treat Rev*. 2020 Mar 1;84.
52. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: The role of histological grade. *Breast Cancer Research*. 2010;12(4).



53. Gosselin M, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. *Virchows Archiv*. Springer Verlag; 2018. p. 697–703.

54. Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. *PET Clin.* 2018;13(3):339–54.
55. Barbara L. Hoffman M, John O. Schorge M, Joseph I. Schaffer M, Lisa M. Halvorson M, Karen D. Bradshaw M, F. Gary Cunningham M. *Williams Gynecology*. 2nd ed. United States: McGraw-Hill Inc.; 2012. 333–355 p.
56. Kawiak A. Molecular Research and Treatment of Breast Cancer. *Int J Mol Sci.* 2022;23(17):10–2.
57. Meric-Bernstam F, Johnson AM, Ileana Dumbrava EE, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer. Vol. 25, *Clinical Cancer Research*. American Association for Cancer Research Inc.; 2019. p. 2033–41.
58. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. *Oncologist*. 2009 Apr 1;14(4):320–68.
59. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. *Journal of Clinical Oncology*. 2012 May 20;30(15):1796–804.
60. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. *New England Journal of Medicine*. 2012 Nov 8;367(19):1783–91.
61. Subiyanto D, Kadi TA, Ismayiah I, Abdurrahman N, Utomo YP, Alifiansyah AR, et al. Molekuler Kanker Payudara di RSUD Madiun dan Hubungannya dengan histopatologi. *Media Penelitian dan Pengembangan Kesehatan*. 2021 Dec 13–202.



62. Aryandono T, Harijadi, Soeripto. Hormone receptor status of operable breast cancers in Indonesia: Correlation with other prognostic factors and survival. *Asian Pacific Journal of Cancer Prevention*. 2006;7(2):321–4.
63. Warjianto W, Soewoto W, Alifianto U, Wujoso H. Hubungan Reseptor Estrogen, Reseptor Progesteron dan Ekspresi Her-2/Neu Dengan Grading Histopatologi pada Pasien Kanker Payudara di RSUD dr. Moewardi Surakarta. *Smart Medical Journal*. 2020;3(2):96.
64. Su, Y., Zheng, Y., Zheng, W. et al. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. *BMC Cancer* 11, 292 (2011). <https://doi.org/10.1186/1471-2407-11-292>
65. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. *Breast Cancer Res*. 2010;12(6):R99. doi: 10.1186/bcr2780. Epub 2010 Nov 19. PMID: 21092082; PMCID: PMC3046442.
66. Rahmawati Y, Setyawati Y, Widodo I, Ghazali A, Purnomosari D. Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor Size. *Asian Pac J Cancer Prev*. 2018 Jan 27;19(1):161-166. doi: 10.22034/APJCP.2018.19.1.161. PMID: 29373908; PMCID: PMC5844611.
67. Widodo I, Dwianingsih EK, Anwar SL, Fx Edianti T, Utoro T, Aryandono T, Soeripto. Prognostic Value of Clinicopathological Factors for Indonesian Breast Carcinomas of Different Molecular Subtypes. *Asian Pac J Cancer Prev*. 2017 May 1;18(5):1251-1256. doi: 10.22034/APJCP.2017.18.5.1251. PMID: 28610410; PMCID: PMC5555531.



68. El-H, Abd El hafez A, Shawky Ael-A, Arafa M. Immunohistochemistry-based study of breast carcinoma in Egyptian women: a clinicopathologic study on 125

patients. Ann Diagn Pathol. 2014 Feb;18(1):21-6. doi:
10.1016/j.anndiagpath.2013.10.005. Epub 2013 Oct 30. PMID: 24321463.

69. Miron L, Marinca A, Marinca M, Miron I. Cancerul mamar triplu negativ--spre o nouă entitate [Triple-negative breast cancer--towards a new entity]. Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):51-8. Romanian. PMID: 18677903.

